DTx in 2024: Where Are We With Business and Reimbursement Models? (Andy Molnar)
In the last few years, we've witnessed a whirlwind of developments in the world of Digital Therapeutics (DTx) - from FDA approvals sparking optimism for the industry, to the establishment of regulatory frameworks in countries like Germany, France, and Belgium. \nHowever, in 2023, the industry faced a stark reality check, marked by the fall of some key players and healthcare systems' hesitancy towards embracing and financing these innovations. This turbulence has reshaped strategies and raised critical questions about the future of DTx.\n\U0001f50d In this episode learn more about: \n\U0001f4ca The current state of the DTx industry in 2024,\n\U0001f5e3\ufe0f Key debates of digital therapies industry players,\n\U0001f310 Advocacy efforts pushing the boundaries for global adoption,\n\U0001f680 Strategies to accelerate the integration of digital therapies worldwide.\n\nNewsletter: fodh.substack.com\nWebsite: www.facesofdigitalhealth.com